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Context: TBI is a recognized cause of hypopituitarism in adults but the prevalence after childhood 
TBI remains controversial. Objective: To investigate long-term endocrine outcomes and quality of life 
(PedsQL and QoL-AGHDA [Quality of Life in Adult Growth Hormone Deficiency Assessment]) 
following childhood TBI. Design: Prospective study. Methods: Participants with moderate/severe TBI 
(n=31) and controls (n=17). Mean (range) age 19.8±4.2 (11-26), time post-TBI 9 (7-11) years. 
Detailed endocrine evaluation of stimulated (insulin tolerance test [ITT]) and spontaneous GH 
secretion (overnight profile) was undertaken in the TBI group; QoL and neuroimaging in both groups. 
Results: No participant had seizures, short stature, precocious puberty or hypothyroidism. In 6/25 the 
ITT GH response was below age-defined cut-offs and cortisol <500 nmol/l in 2/25. Mean spontaneous 
GH secretion was <3.1 mcg/l in 16/22 but peak GH was low only in 1/22 profiles. One patient had 
abnormal spontaneous and stimulated GH secretion and hypogonadism. Fatigue and depression 
scores were higher in TBI patients (p=.011 and p=.020). Fatigue correlated with measures of 
spontaneous but not stimulated GH secretion. Overall QoL (PedsQL) did not differ between groups 
but specific attributes of health state (cognition, memory) were impaired in TBI patients. Pituitary 
neuroimaging was normal in all participants. 
Conclusions: Fatigue and depression were common 8-10 years post-childhood TBI. One individual 
had GHD (1/22) using rigorous diagnostic criteria. A single ITT potentially over-diagnosed GHD in 
25% (6/25) without clear correlation with symptoms underlying the importance of using two diagnostic 





Traumatic brain injury (TBI) is the leading cause of acquired neurological morbidity in UK children with 
annual hospital admission of 1/ 100-200 children (1). The Glasgow Coma Scale score (GCS) has 
been used to signify the severity of TBI (GCS of 13-15 signifies mild, 9-12 moderate and 8 or below 
severe TBI). TBI has been associated with permanent post-traumatic hypopituitarism (PTHP) (2) in 
adults. Reported prevalence ranges in the acute post-traumatic period from 5% up to 80% (3). This 
variation reflects methodological differences in inclusion criteria, time since TBI (higher prevalence 
reported early following TBI), use of different diagnostic tests and cutoff values. Although multiple 
hormone deficiencies have been described, most TBI survivors have a single axis (4) deficiency, 
usually GH deficiency (GHD). There is however much less substantive evidence of PTHP prevalence 
and clinical outcome after childhood TBI. In a study of 198 paediatric survivors of TBI with MRI 
changes, all participants had normal pituitary function using two stimulation tests (5) while in a more 
recent study, GHD was confirmed in 5/61 children with severe TBI who were retested 5 years post-
TBI (6). Conversely, other studies reported 10-40% incidence of hypopituitarism 1-3 years post-TBI 
but without however using stringent diagnostic criteria (7, 8). Currently, there is no consensus for 
routine surveillance after childhood TBI. Even growth monitoring – a key indicator of childhood 
pituitary function – is not consistently undertaken post-TBI (9). 
KHINES (Kids’ Head Injury Neuro-Endocrine Study) aimed to determine the long term prevalence of 
neuroendocrine consequences following childhood TBI with detailed endocrine studies, including 
assessment of physiological and stimulated GH secretion. 
Materials and Methods 
Ethical Approval 
The study protocol was approved by the North Somerset and South Bristol Research Ethics 
Committee (Study No CH/20090/3273). Informed consent/assent was obtained from participants or 





Inclusion criteria: all Participants of the Kids’ Head Injury Study (KHIS) – a prospective 
neuropsychology study of children, recruited immediately post-TBI (2002-2004). Control participants 
in KHIS were non-injured school children matched for age, sex, socio-economic status and pre-TBI 
academic attainment. The original research team psychologist contacted KHIS participants asking if 
they would consider participating in KHINES. Recruitment was over two years (2011-2013). Age 
(range) at assessment was 19.8 (11.3-26.6) years and time since TBI was 9.0 (6.8-10.8) years. There 
were no differences between participating and non-participating TBI individuals with regards to age, 
gender, time since TBI, duration of post-traumatic amnesia, days in intensive care and type of 
structural abnormalities on acute neuroimaging (extradural/subdural haemorrhage, diffuse axonal 
injury or skull fracture). 
Exclusion criteria included pregnancy, history of significant pre-TBI endocrine dysfunction, 
psychological or non-TBI medical problems and drugs (steroids) affecting interpretation of results and 
repeat TBI (any severity).  
Clinical and Auxological Assessment 
Detailed data concerning the severity and mechanism of TBI and outcomes were available from the 
KHIS database. All participants were examined by the same researcher and were asked to complete 
questionnaires to assess quality of Life (QoL), fatigue, and had neuroimaging unless contra-indicated. 
In addition, TBI participants underwent detailed endocrine investigations.  
Questionnaire measures 
The Paediatric Quality of Life Inventory (PedsQL 4.0) has been applied to children with paediatric TBI 
and has detected cognitive differences among groups of children with varying severities of TBI (10). 
The Fatigue Scale (Chalder et al (11)) is a self-report measure of tiredness. It produces a total score, 
with subscores reflecting mental fatigue (4 items), and physical fatigue (7 items). The Beck 
Depression Inventory (BDI-II) (12) is a 21-item self-report instrument for measuring the degree of 
depression in adults and adolescents. The Quality of Life Assessment of Growth Hormone Deficiency 




developed specifically to detect deficits in areas that are affected in adults with GHD. A score of 11 or 
more is suggestive of perceived impairment of quality of life (13). 
Neuroimaging 
Unless contraindicated, study participants were examined on a 3T MRI scanner (Magnetom Skyra, 
Siemens Medical Systems). Sagittal and coronal T2 TSE (TR/TE 4430/89ms; thickness 2mm; FOV 
190; resolution 0.5x0.5mm) and T1 weighted images (TR/TE 500/2.93; thickness 2mm; FOV 190) 
were obtained and were reported by the same expert consultant neuro-radiologist blinded to clinical 
details. Pituitary volume was calculated using the ellipsoid formula. 
Endocrine Investigations  
Ethics approval for blood tests was obtained only in TBI participants. Baseline Investigations included 
free-T4, TSH, testosterone (males), estradiol (females), LH, FSH, prolactin (PRL), IGF-1, IGF-BP3 
and plasma osmolality. 
GH status was assessed by 12 hour overnight GH profile (8 pm to 8 am and sampling every 15 
minutes followed by an insulin tolerance test the following morning (ITT). Blood sampling commenced 
1h after catheter insertion, participants were ambulatory, had an evening meal but only water from 
midnight. Participants slept and woke at their usual time. Blood samples were kept overnight at 5oC 
then centrifuged and stored at -70oC until assayed within 3 months. GH profiles were compared with 
published data of 43 healthy participants (16.1±1.1 years) using the same GH assay with 30 minute 
sampling. Mean spontaneous, nocturnal GH secretion in this group was 6.7±2.9 (3.1-15.6 mcg/l) (14). 
For the Insulin tolerance test (ITT), soluble insulin (0.15 U/kg) was given i.v. to induce hypoglycaemia 
(glucose <2.2 mmol/l). GH and cortisol were assayed at -15, 0, 30, 60, 90 and 120 min. Diagnostic 
criteria used for GHD: young adult <3 mcg/l, transition age <5 mcg/l and paediatric <6.7 mcg/l (15); 
cortisol 500 nmol/l. 
Assays 
GH and cortisol were assayed in duplicate using a commercial electrochemiluminescence 
immunoassay (“hGH” and “cortisol”, Roche Diagnostics GmbH). Intra- and inter-assay coefficients of 




limit of detection 0.03mcg/L; Cortisol 1.5% and 1.7% at concentrations of 352 nmol/L and 717 nmol/L 
and limit of detection 0.5 nmol/L. Serum IGF-1 and IGF-BP3 were assayed by Immulite 1000. Intra-
assay and inter-assay CV’s were: IGF-I under 4% and 8% respectively for concentrations between 6-
120 nmol/L; IGF-BP3 5.6% and 9.9%; 3.5% and 7.5% at concentrations of 1.6 and 6.8mg/L 
respectively. 
FT4, TSH, LH, FSH, and PRL blood levels were measured by ECLIA, using a Modular E170 (Roche 
Diagnostics) with maximal inter-assay CV of 5.0%. 
GH Profile Analysis 
Analysis of GH secretion was done using deconvolution. Deconvolution is the method by which the 
combined result of interlinked processes (i.e. secretion, distribution, and elimination) is untangled to 
reveal the underlying components. The AutoDecon deconvolution algorithm (16) that was used in this 
study uses the assay as a scale factor and automatically inserts presumptive peaks after testing them 
for significance. The following initialization settings were set: basal secretion: zero; concentration at 
time zero: zero; elimination half-life: 10-20 minutes; standard deviation of the secretion events: one-
half of the data sampling interval; and zero secretion events. Peak spontaneous GH below the 
diagnostic ITT cutoff (17) or average overnight GH secretion below 3.1 mcg/l were used as diagnostic 
criteria (3.1 mcg/l was the lowest mean GH level reported in 43 healthy subjects of similar age using 
the same GH assay as in KHINES (14)). 
Approximate Entropy (ApEn) was used to assess the serial orderliness (regularity) of GH secretion. 
ApEn is a number between 0 and 1 with larger values corresponding to greater randomness (18). The 
parameters used in this analysis (m=1 and r=20%) are reproducible in endocrine practice (19). 
Statistics 
Data are expressed as mean±standard deviation (mean±SD) or median (median [range]) if not 
normally distributed. Auxological measurements were converted to Standard deviation scores (SDS) 
for comparisons (20). Parametric (t-test) and non-parametric tests used were (Mann Whitney U and 
Wilcoxon signed ranks for paired data). Associations and agreement between variables were 






Forty eight out of 117 (31/61 mod/sev TBI and 17/56 healthy controls) agreed to participate in 
KHINES. TBI and control groups were similar with regards to height SDS (0.23 [-2.0 – 2.8] vs 0.43 [-
1.1 – 2.8], p=.462), weight SDS (0.49 [-2.6 – 3.8] vs 0.79 [-0.4 -3.9], p=.238) and BMI SDS (0.45 [-1.8 
– 3.2] vs 0.64 [-0.65 – 3.45], p=.330). None of the participants had short stature compared with UK 
population standards. 
Baseline endocrine function 
All participants had normal thyroid and posterior pituitary function. Post-pubertal males had 
testosterone levels within the normal range. 
Of the 11 female participants, 7 were post-pubertal, 3 pubertal (Tanner stage 3-4) and one was 
prepubertal (11.3 years old). Five were taking oral contraception. One post-pubertal female with 
secondary amenorrhea following TBI had low levels of oestradiol (<50 pmol/L), gonadotropins, IGF-1 
and IGFBP3 (-2.4 and -2.1 SDS respectively). All male participants were pubertal (n=9, Tanner stage 
4) or post-pubertal (n=11, Tanner stage 5). 
Stimulated Growth hormone and cortisol secretion 
Twenty-five of 31 TBI participants had a stimulation test (ITT). In 6/25 (4 male) the GH response to 
ITT was suboptimal using age-appropriate cut-off values (Table 1). In one male participant the cortisol 
peak was also suboptimal (483 nmol/l). One female participant with amenorrhea and low 
gonadotropin levels (see above), demonstrated normal cortisol (584nmol/l) but abnormal stimulated 
GH response (peak GH 3.7 mcg/l). Another female participant with suboptimal cortisol response 
(392nmol/l) had normal GH response to ITT (peak GH 6.7 mcg/l). 
IGF-1 SDS was not different between participants with normal and abnormal stimulated GH response 
(-.48±1.1 vs -.74 ±.82, p=.86) and peak stimulated GH response did not correlate with IGF-1 (ρ =.21, 




Spontaneous Growth Hormone Profiles 
Data from 22 overnight GH profiles (8 participants were not able to stay overnight but 3 had an ITT 
and one profile was incomplete) are shown in Table 2 and Figure 1. All 22 participants who had an 
overnight profile also had an ITT. 
As expected there is a difference between male and female profiles, with increased basal GH 
secretion in females and increased ApEn indicating higher temporal irregularity in overnight GH 
secretion. There was a trend to lower peak GH in females but this did not reach statistical 
significance. Overall, mean GH secretion was significantly lower compared to that reported in healthy 
individuals (2.2±1.3 vs 6.1±2.6 mcg/l, p<.0001) (14). Mean GH was under 3.1 mcg/l in 16/22, 4 of 
whom had an abnormal response to ITT (indicating poor agreement between tests when using the 
above criteria [Kappa .096, p=.49]). Three of these 4 participants had peak overnight GH above the 
age-related cutoff and IGF-1 SDS above -0.5. The fourth participant had low peak overnight GH of 2.7 
mcg/L and low IGF-1of -2.4. Although 4 had an abnormal GH response to ITT (with low mean 
overnight secretion), 12 demonstrated a normal response. Neurosecretory dysfunction (normal 
stimulated but suboptimal spontaneous GH responses) has been described (21) although its clinical 
significance is not clear. 
Pulsatility was preserved in all but one participant (female with amenorrhea and GHD) as at least 4 
secretory events were detected with deconvolution analysis in all other profiles (including ones where 
the GH concentration curve would suggest a smaller number of secretory events as shown in Figure 
1. 
In contrast to ITT results, measures of spontaneous GH secretion (average, maximum, mean 
secretion pulse mass) correlated with IGF-1 levels (r=.74, r=.52, r=.75, all p<.05). IGF-1 levels were 
also lower in the subgroup of TBI patients with mean, overnight GH secretion under 3.1 mcg/l 
(33.4±7.1 vs 45.7±7.1 nmol/L, p=.003, 95% CI of difference 4.62-19.87). 
There was no strong correlation between peak stimulated and peak spontaneous GH levels (ρ=.17, 
p=0.45). 
In descending order and using different diagnostic criteria and their combinations to estimate the 
frequency of insufficient GH secretion, 16/22 (72%) had low mean overnight GH secretion, 6/25 (24%) 




abnormal (1/22, 5%). Mean overnight and stimulated GH secretion were also abnormal in the same 
profile. 
 
Quality of life 
Only TBI participants (9/30), but no controls had a Total PedsQL score of less than 69.7% which is 
the level for detecting QoL problems in children with chronic health conditions. QoL-AGHDA scores in 
adult TBI patients (14/20 responded) indicated poor QoL (10.7±6.9, 8/14 had a score >11) and were 
higher when compared to age and gender-weighted, general population UK data (difference 4.86, 
95% CI 1.3-8.3, p<.01). To further examine potential bias because of non-responders, the analysis 
was repeated using mean AGHDA scores from the general population (5.8 for males, 6.6 for females) 
for non-responders (22). QoL-AGHDA scores were again higher in the adult TBI group but the 
difference was smaller (difference 2.68, 95% CI -.22 – 5.58, p=.068). However, this cannot entirely 
rule out bias if, for example, non-responders had scores better than average. 
Q0L-AGHDA scores correlated with fatigue scores (r=.62, p=.002) but not with measures of GH 
secretion. 
Fatigue 
Fatigue scores were higher in TBI (3.2±3.3) vs control group (.43 ±.85) using bimodal scoring (scale 
0-11) (p<.001). Bimodal scores of ≥3 [239] or ≥16 (Likert) are recommended for identifying significant 
fatigue; 13/28 TBI participants fulfilled these criteria compared with 1/14 in the control group (p=.011). 
Fatigue scores correlated negatively with PedsQL scores (ρ= -.68, p<.001); participants with higher 
levels of fatigue having poorer QoL (p<.001). Although fatigue was not associated with measures of 
stimulated GH secretion or IGF-1/IGFBP3, mean secretion pulse height in overnight profiles was 
significantly lower in male participants with fatigue (p=.022). 
In four TBI participants (2 male) the bimodal fatigue score was above 9 which is seen in Chronic 
Fatigue Syndrome (CFS) patients (23). Two of them completed all endocrine investigations. Both had 
normal stimulated GH response to ITT (6.2 and 14.3 mcg/L) but their mean overnight secretion was 





35/48 participants (14 controls, 21 TBI) had a head MRI scan (10 TBI were excluded due to metallic 
implants and 3 controls due to the possibility of metal fragments in their eyes). 
In TBI participants 15/35 scans were abnormal. Reported abnormalities included contusions in 11, 
white matter shearing injury in 1, frontal lobe cavities in 1, reduced brain volume in 1 and acoustic 
neuroma in 1 (incidental finding). Pituitary morphology (both anterior and posterior) was normal in all 
participants and pituitary size did not differ between groups (TBI vs control, 1727±585 vs 1480±493 
mm3, p=.884). Pituitary volume did not correlate with measures of spontaneous or stimulated GH 
secretion. 
Discussion 
KHINES demonstrated persisting abnormalities in the GH/IGF-1 axis in TBI survivors including 
multiple pituitary hormone deficiency in one participant. It also highlights the inherent difficulties in 
assessing GH status using both stimulated and/or spontaneous GH secretion in a dynamic hormone 
system. Measurement of peak level of spontaneous GH secretion (or number of peaks above a 
predefined cut-off) has been reported to provide higher diagnostic accuracy than the stimulated 
response (24) but the definition of a significant GH spontaneous peak remains controversial. Although 
studies in prepubertal children or adults have used a fixed GH level to define a normal response (17, 
25), in KHINES we used strict criteria of a single peak above the standard age-related cut-off (same 
level used in ITT). 
In a similar study by Wamstad et al (25) that enrolled children and adolescents (age range 8-21 
years) 3-4 years post-TBI, the prevalence of GHD was 17% based on overnight GH secretion and 
27% based on the stimulation test. Stimulation test results are comparable (KHINES 24% [6/25]) but 
overnight GH secretion in KHINES was abnormal in 5% (1/22) using the age-related cut-off to classify 
abnormal GH profiles. Results are comparable if the same not age-related cutoff of 5mcg/L is used 
(3/22 [14%]). 
Although abnormalities in the GH axis have been identified, anthropometric and physical function 
scores in our study group of TBI survivors were not different to the control group. Adult height was not 




were observed in TBI survivors. There was no association between QoL, depression scores or fatigue 
and GH status as assessed using the ITT. This is in agreement with a previous report (26). There was 
however an association with spontaneous GH secretion as peak secretion amplitude was reduced in 
TBI males with fatigue. A similar pattern of GH secretion with reduced GH pulse amplitude but normal 
secretory event frequency and stimulated GH secretion has been described in patients with 
fibromyalgia. These patients demonstrate normal pituitary responsiveness to GHRH supporting the 
hypothesis of dysregulation at the hypothalamic or higher level (27). KHINES participants showed a 
similar pattern which has previously been described as neurosecretory dysfunction (normal stimulated 
but suboptimal spontaneous GH responses) (21). 
These interesting but subtle associations do not necessarily demonstrate causality and could be 
associated phenomena. However, if present, it would be reasonable to anticipate that untreated 
PTHP could impede recovery and rehabilitation of TBI survivors and contribute to the long-standing 
problems with fatigue, poorer HRQL and cognitive impairment. 
The question remains as to what is the best way to assess GH axis integrity in children post TBI 
considering the low a priori likelihood of hypopituitarism as demonstrated in KHINES. We propose a 
pragmatic approach utilizing two GH stimulation tests for TBI patients with low IGF-1 (or IGF-1 SDS < 
-2) and/or biochemical or clinical evidence of pituitary hormone deficiency. Current UK guidelines 
indicate a single dynamic test for patients with a known underlying cause for GHD but in light of our 
findings we propose that TBI patients with significant fatigue or other symptoms affecting QoL but 
normal baseline endocrinology do need two abnormal stimulation tests (or combination of stimulation 
test and overnight profile if feasible) to diagnose GHD. It is also important to ensure that stimulation 
tests that involve administration of GHRH are avoided as these will underdiagnose GHD secondary to 
hypothalamic dysfunction.  
The main limitation of KHINES was not having a control group for the endocrine investigation arm 
involving blood tests. Recruitment, however, was high and there was little variability with regards to 
time from injury (all between 7-11 years). KHINES is also one of the few paediatric TBI studies that 
used two endocrine tests to assess GH status and the first one to our knowledge that has used a 





KHINES has demonstrated that the identification of PTHP after childhood TBI is challenging, but if 
stringent diagnostic criteria are used, long term prevalence of PTHP in survivors of childhood TBI is 
less frequent than has been reported previously. Clinical criteria suggesting pituitary dysfunction 
obviously need investigation but with two GH stimulation tests especially in the context of low IGF-1 or 
biochemical evidence of other pituitary hormone deficiency. 
Fatigue and depression are still prevalent 8-10 years post-childhood TBI. Fatigue correlated with 
measures of spontaneous but not stimulated GH which may suggest dysfunction at the hypothalamic 
or higher rather than pituitary level. Any role for intervention with GH treatment requires further study 
in this cohort of patients who do not present with a typical GHD phenotype. 
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